<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603288</url>
  </required_header>
  <id_info>
    <org_study_id>SNT-III-012-E</org_study_id>
    <nct_id>NCT03603288</nct_id>
  </id_info>
  <brief_title>Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)</brief_title>
  <acronym>SIDEROS-E</acronym>
  <official_title>A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santhera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the long-term safety and efficacy of idebenone in
      patients with Duchenne muscular dystrophy (DMD) who completed the SIDEROS study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, single-group, multi-center extension study in patients with DMD
      receiving glucocorticoid steroids who participated in the SIDEROS study and who meet all the
      inclusion criteria and none of the exclusion criteria for this extension study.

      The study consists of 4 study visits scheduled every 6 months (Visit 1/Baseline, Visit 2/Week
      26, Visit 3/ Week 52 and Visit 4/ Week 78), and a follow-up visit 4 weeks after treatment
      discontinuation. Visit 8/Week 78 in SIDEROS study is also SIDEROS-E Visit 1/Baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label Extension Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events, as per ICH Topic E2A</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events, as per ICH Topic E2A</measure>
    <time_frame>4 weeks after discontinuation of treatment</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with premature discontinuations of study treatment due to adverse events.</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal safety laboratory parameters.</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal safety laboratory parameters.</measure>
    <time_frame>4 weeks after discontinuation of treatment</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal vital signs.</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal vital signs.</measure>
    <time_frame>4 weeks after discontinuation of treatment</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal ECG.</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To assess the long-term safety of idebenone in DMD patients who completed the SIDEROS study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Forced Vital Capacity (FVC) as percent of predicted (FVC%p).</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To describe the long-term evolution of respiratory function in idebenone-treated DMD patients who completed the SIDEROS study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Peak Expiratory Flow (PEF) as percent of predicted (PEF%p)</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To describe the long-term evolution of respiratory function in idebenone-treated DMD patients who completed the SIDEROS study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) as percent of predicted (FEV1%p)</measure>
    <time_frame>From baseline until visit 4 (week 78)</time_frame>
    <description>To describe the long-term evolution of respiratory function in idebenone-treated DMD patients who completed the SIDEROS study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>idebenone 150 mg film-coated tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idebenone 150 mg film-coated tablets</intervention_name>
    <description>900 mg idebenone/day</description>
    <arm_group_label>idebenone 150 mg film-coated tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completion of the SIDEROS study at Visit 8/ Week 78

          2. Signed and dated Informed Consent Form for SIDEROS-E

        Exclusion Criteria:

          1. Patients who discontinued SIDEROS study prematurely (i.e. did not attend all visits
             from V1 to V8)

          2. Safety, tolerability or other issues arising during the course of the SIDEROS study
             which in the opinion of the Investigator may put the patient at significant risk or
             may interfere significantly with the patient's participation in the SIDEROS-E study

          3. Use of any investigational drug other than the study medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jodi Wolff</last_name>
    <phone>+1 (520) 373-0069</phone>
    <email>sideros@santhera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham, Child Health Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bradley Troxler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cori Daines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leigh Ramos-Platt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Integrative Rare Disease Research, Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Han Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa, Department of Pediatrics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kathy Matthews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston, Harvard Medical School, Department of Neurology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Basil Darras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gillette Children's Specialty Healthcare</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Randal Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurosciences Institute, Neurology - Charlotte Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnny Jones, MS</last_name>
      <phone>704-446-1349</phone>
      <email>Johnny.Jones@carolinashealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Ranzinger</last_name>
      <phone>704-446-0803</phone>
      <email>Lisa.Ranzinger@carolinashealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cuixia Tian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109-1988</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alesia Cocklin, RN</last_name>
      <phone>216-778-2057</phone>
      <email>acocklin@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Andre Prochoroff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia, Division of Pulmonology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-1771</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oscar Henry Mayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gottfried von Preyer'sches Kinderspital</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernert Guenther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Buyse, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gunnar Buyse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Servais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de neuropédiatrie Pôle Pédiatrie CHRU de Lille - Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marie Cuisset, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Gui de Chauliac, Département de pédiatrie - neuropédiatrie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulkrike Walther-Louvier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel Dieu, Service Explorations Fonctionnelles - Centre de Référence de Maladies Neuromusculaires rares</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yan Pereon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I-Motion - Plateforme d'essais cliniques pédiatriques Hôpital Armand Trousseau bâtiment Lemariey porte 20, 2ème étage</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Odile Boespflug-Tanguy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des enfants, Pédiatrie Neurologie et infectiologie Pôle enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claude Cancès, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf, Department of Paediatrics</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessika Johannsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for neuromuscular disorders, Dr. v. Haunersche Kinderklinik, Universität München</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfgang Muller-Felber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Eugenio Medea</name>
      <address>
        <city>Bosisio Parini</city>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annamaria Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Malattie Neuromuscolari, Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scientific Coordinator Nemo Sud Clinical CenterAOU Policlinico &quot;G. Martino&quot;</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giuseppe Vita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Clinico NEMO (NEuroMuscular Omnicentre), Niguarda Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valeria Sansone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servizio di Cardiomiologia e Genetica Medica AOU Università degli Studi della Campania Luigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luisa Politano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reparto Di Neurologia dell'Osperdale Di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Pegoraro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Clinica Neurologica e Psichiatrica dell'Eta Evolutiva della Fondazione IRCCS &quot;C. Mondino&quot; di Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angela Berardinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eugenio Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu Neuropediatra, Unidad de patologia nueromuscular, Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andres Nascimento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe de Valencia Avinguda de Fernando Abril Martorell Servicio de Neurologia Torre D</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Jesus Vilchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for neuromuscular disorders, Universitäts-Kinderspital beider Basel (UKBB)</name>
      <address>
        <city>Basel</city>
        <zip>4301</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospital NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne-Marie Childs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL, National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rosaline Quinlivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pinki Munot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility Level 6 Leazes Wing Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michela Guglieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Jones and Agnes Hunt Orthopaedic Hospital</name>
      <address>
        <city>Oswestry</city>
        <zip>SY10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Willis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tracey Willis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.siderosdmd.com/</url>
    <description>SIDEROS study website</description>
  </link>
  <link>
    <url>https://www.clinicaltrials.gov/ct2/show/NCT02814019?term=SIDEROS&amp;rank=1</url>
    <description>SIDEROS study clinicaltrials.gov entry</description>
  </link>
  <reference>
    <citation>Buyse GM, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T; DELOS Study Group. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015 May 2;385(9979):1748-1757. doi: 10.1016/S0140-6736(15)60025-3. Epub 2015 Apr 20.</citation>
    <PMID>25907158</PMID>
  </reference>
  <reference>
    <citation>McDonald CM, Meier T, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, Rummey C, Leinonen M, Spagnolo P, Buyse GM; DELOS Study Group. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2016 Aug;26(8):473-80. doi: 10.1016/j.nmd.2016.05.008. Epub 2016 May 12.</citation>
    <PMID>27238057</PMID>
  </reference>
  <reference>
    <citation>Buyse GM, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, Rummey C, Leinonen M, Mayer OH, Spagnolo P, Meier T, McDonald CM; DELOS Study Group. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy. Pediatr Pulmonol. 2017 Apr;52(4):508-515. doi: 10.1002/ppul.23547. Epub 2016 Aug 29.</citation>
    <PMID>27571420</PMID>
  </reference>
  <reference>
    <citation>Mayer OH, Leinonen M, Rummey C, Meier T, Buyse GM; DELOS Study Group. Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2017;4(3):189-198. doi: 10.3233/JND-170245.</citation>
    <PMID>28869486</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>respiratory function in DMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

